Search results for: Kenneth Arrow
Filter search results
OHE Lunchtime Seminar: How Do We Measure the ‘Value’ in Value-based Care?
19 August 2019
…treat the illness, not the person. They chase narrow biomedical indicators, which, while important, don’t capture all that matters to the patient. Prof Stephen McKenna will review current methods of…
The NICE Health Technology Evaluation Manual: A Fresh Perspective Needed?
16 March 2022
…and should be presented separately from the main analysis, which always takes a narrow NHS/PSS perspective. In addition, no guidance was provided on how they should be measured or presented,…
NICE’s severity modifier: a step in the right direction, but still a long way to go
23 March 2022
…first introduced a ‘severity modifier’ – the ‘end-of-life (EOL) criteria’ – in 2009. The EOL criteria were criticised for being too narrow and not considering improvements in quality of life….
Pharmaceutical Research: the Case for Growth in Britain
1 July 1967
…narrow context of the National Health Service, the pharmaceutical industry may have been judged primarily on its ability to manufacture and supply good quality medicines at the lowest possible prices….
Leukaemia: Towards Control
6 January 1980
…chemotherapy and the extension of facilities for bone marrow transplantation in Britain, an operation which if made more widely available and/or applicable might reduce further the number of leukaemia deaths…
Health, Education and General Practice
1 January 1986
…practice is a broad avenue rather than a narrow gangplank. Incidentally, the conclusions from the 1985 meeting form a sharp contrast to those from an earlier meeting organised by the…
Organ Transplantation
1 July 1991
…and pancreas, while recognizing the omission of the important area of tissue transplants, concerning bone, bone marrow, cornea, skin and heart valves. The OHE believe that the area of solid…
Industrial Policy and the Pharmaceutical Industry
1 January 1995
…European Community, Japan and the US are by Yarrow, and Professors Neary and Scherer, respectively. In the fourth paper Hale and Towse assess how valuable the UK-based pharmaceutical industry is…